Pleiotropic effects of incretins and antidiabetics with incretine mechanism
Orvosi Hetilap, 2013 Discovery of physiological and pharmacological characteristics of incretins (glucagon-like peptide-1 and glucose-dependent insulinotrop polypeptide), and the introduction of various products of those into the clinical practice has fundamentally changed blood glucose lowering therapy in type 2 diabetes.
Winkler, Gábor
openaire +3 more sources
Hyperglycaemia induced osteoporosis: Is there a hope with dipeptidyl peptidase-4 inhibitors?
Health Sciences Review, 2023 Diabetes mellitus and osteoporosis are chronic illnesses associated with adverse health outcomes. Studies have reported common linkages between energy and bone metabolism.
Faraha Ahmed +8 more
doaj +1 more source
Best Achievements in Clinical Medicine in Diabetes and Dyslipidemia in 2020 [PDF]
Endocrinology and Metabolism, 2021 Over the last two decades, our understanding of diabetes and treatment strategies have evolved tremendously, from scientific, mechanistic, and human perspectives.
Eun-Jung Rhee +2 more
doaj +1 more source
Experimental and Emerging Free Fatty Acid Receptor Agonists for the Treatment of Type 2 Diabetes
Medicina, 2022 The current management of Type 2 Diabetes Mellitus (T2DM) includes incretin-based treatments able to enhance insulin secretion and peripheral insulin sensitivity as well as improve body mass, inflammation, plasma lipids, blood pressure, and ...
Angelo Maria Patti +10 more
doaj +1 more source
Role of endogenous incretins in the regulation of postprandial lipoprotein metabolism [PDF]
, 2022 Objective: Incretins are known to influence lipid metabolism in the intestine when administered as pharmacologic agents. The aggregate influence of endogenous incretins on chylomicron production and clearance is less clear, particularly in light of ...
Hartmann, Bolette +17 more
core +1 more source
To be or not to be—an incretin or enterogastrone? [PDF]
Gut, 2006 Glucagon-like peptide 1 does not comfortably fulfil the criterion of a gut derived factor responsible for an enhanced meal related insulin response; it appears logical to add the definition of a "physiological incretin hormone".
Horowitz, M., Nauck, M.
openaire +3 more sources
Incretin‐based therapies [PDF]
Journal of Diabetes, 2012 AbstractIncretin‐based therapies have established a foothold in the diabetes armamentarium through the introduction of oral dipeptidyl peptidase‐4 inhibitors and the injectable class, the glucagon‐like peptide‐1 receptor agonists. In 2009, the American Diabetes Association and European Association for the Study of Diabetes authored a revised consensus ...
Stonehouse, Anthony H +2 more
openaire +2 more sources
Asian Subpopulations May Exhibit Greater Cardiovascular Benefit from Long-Acting Glucagon-Like Peptide 1 Receptor Agonists: A Meta-Analysis of Cardiovascular Outcome Trials [PDF]
Diabetes & Metabolism Journal, 2019 BackgroundBased on reported results of three large cardiovascular outcome trials (CVOTs) of glucagon-like peptide 1 receptor agonists (GLP-1 RAs), we aimed to investigate the overall effect of GLP-1 RAs on major adverse cardiovascular events (MACEs) and ...
Yu Mi Kang +8 more
doaj +1 more source
Metformin in prediabetes: key mechanisms for the prevention of diabetes and cardiometabolic risks
Медицинский совет, 2022 Today, prediabetes is regarded by the world medical community as early diabetes mellitus. The accumulated research evidence shows that prediabetes is characterized by a spectrum of complications that are similar to those of diabetes mellitus, which means
A. Yu. Babenko
doaj +1 more source
Cell Reports, 2014 Incretins, hormones released by the gut after meal ingestion, are essential for maintaining systemic glucose homeostasis by stimulating insulin secretion.
Ghupurjan Gheni +21 more
doaj +1 more source